Novynette (Desogestrel, Ethinylestradiol)

Desogestrel, the active ingredient in Novynette, is a progestogen presented as a combined oral contraceptive for systemic use. It prevents ovulation and stabilises the uterine lining to provide reliable birth control for women of reproductive age. GNH USA supplies Novynette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novynette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novynette is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.

- Contraception: Provides effective prevention of pregnancy when taken as directed. - Menstrual cycle regulation: Helps to establish more predictable menstrual bleeding patterns. - Acne improvement: Reduces androgen‑driven skin lesions in some women using the pill. - Endometriosis symptom relief: Alleviates pain associated with endometriosis through hormonal suppression. - Polycystic ovary syndrome (PCOS) management: Assists in regulating cycles and reducing hyperandrogenic symptoms.

Novynette, like other combined oral contraceptives, may cause a range of adverse reactions.

Common Side Effects: - Nausea: Mild to moderate stomach upset, especially when starting therapy. - Headache: Tension‑type or migraine‑like headaches. - Breast tenderness: Temporary swelling or discomfort of breast tissue. - Weight change: Slight increase or decrease in body weight. - Mood changes: Fluctuations in mood or mild depressive symptoms. - Spotting between periods: Light bleeding or spotting.

Serious or Rare Side Effects: - Venous thromboembolism: Blood clot formation in deep veins or lungs. - Arterial thrombosis: Stroke or myocardial infarction, particularly in smokers over 35. - Severe hypertension: Sudden, marked increase in blood pressure. - Liver dysfunction: Jaundice or abnormal liver enzyme levels. - Allergic reactions: Rash, itching, swelling, or anaphylaxis. - Gallbladder disease: Inflammation or stones in the gallbladder.

Before prescribing Novynette, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Smoking status: Avoid use in women over 35 who smoke due to increased cardiovascular risk. - Cardiovascular history: Contraindicated in patients with a history of thromboembolic events, stroke, or myocardial infarction. - Liver disease: Use with caution in patients with active liver disease or hepatic dysfunction. - Hypertension: Monitor blood pressure regularly; discontinue if severe hypertension develops. - Migraine with aura: Not recommended for women experiencing migraine with aura. - Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Novynette may interact with several medicines, altering its effectiveness or increasing adverse event risk.

Major Interactions (Avoid): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): Reduce hormonal efficacy, increasing pregnancy risk. - Rifampicin: Decreases plasma concentrations of both estrogen and progestin components. - Certain HIV protease inhibitors (e.g., ritonavir): May increase estrogen levels, raising clot risk.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., amoxicillin, tetracycline): May slightly lower contraceptive effectiveness. - St. John’s wort: Potentially reduces hormone levels, requiring additional contraceptive measures. - Antifungal azoles (e.g., fluconazole): Can increase estrogen exposure, warranting blood pressure monitoring.